Sangeeta Bhatia

Sangeeta N.
Bhatia is the founder of Hepregen Corp.
founded in 2007, Matrisome Bio, Inc. founded in 2023, Glympse Bio, Inc. founded in 2015, and Satellite Biosciences, Inc. founded in 2020 where Dr. Bhatia holds the title of Director.
Dr. Bhatia is also the founder of Port Therapeutics, Inc.,Impilo Therapeutics, Inc...
Dr. Bhatia currently serves as an Independent Director at Vertex Pharmaceuticals, Inc. since 2015, a Professor at Massachusetts Institute of Technology since 2005, a member of the Scientific Advisory Board at Cristal Delivery BV, a member of the Scientific Advisory Board at Maverick Therapeutics, Inc., and a Venture Partner at Catalio Capital Management LP.
Former positions include Member-Medicine Department at The Brigham & Women's Hospital, Inc., Professor at the University of California San Diego from 1998 to 2005, Member of the National Academy of Sciences, Member of the National Academy of Engineering, Member of the National Academy of Medicine (United States), Member of The Broad Institute, Inc., member of the Scientific Advisory Board at Lumicell, Inc., and Member of the David H.
Koch Institute for Integrative Cancer Research.
Education includes undergraduate studies at Brown University, a doctorate from Harvard Medical School, and a doctorate from Massachusetts Institute of Technology conferred in 1997.